1. The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
- Author
-
Nicole Hustedt, Henrique Melo, Dheva Setiaputra, Jessica Desjardins, Artur Veloso, Rachel K. Szilard, Shou Yun Yin, Alejandro Álvarez-Quilón, Michael Zinda, Timothy F. Ng, Meagan Munro, Robert Papp, Daniel Durocher, Mara De Marco Zompit, Yibo Xue, Giovanni Martino, Jordan T.F. Young, Nathalie Moatti, Salomé Adam, Natasha Chaudhary, Vivek Bhaskaran, Manuel Stucki, Sylvie M. Noordermeer, Toshiro K. Ohsumi, Silvia Emma Rossi, University of Zurich, and Durocher, Daniel
- Subjects
Genome instability ,Cancer Research ,endocrine system diseases ,610 Medicine & health ,Synthetic lethality ,Biology ,Genomic Instability ,03 medical and health sciences ,0302 clinical medicine ,Chromosomal Instability ,Neoplasms ,Humans ,CRISPR ,1306 Cancer Research ,Homologous Recombination ,skin and connective tissue diseases ,Mitosis ,Gene ,030304 developmental biology ,0303 health sciences ,Nuclear Proteins ,DNA ,10174 Clinic for Gynecology ,Cell biology ,DNA-Binding Proteins ,Oncology ,Essential gene ,030220 oncology & carcinogenesis ,Cancer cell ,2730 Oncology ,Carrier Proteins ,Synthetic Lethal Mutations ,Homologous recombination - Abstract
BRCA1/2-mutated cancer cells adapt to the genome instability caused by their deficiency in homologous recombination (HR). Identification of these adaptive mechanisms may provide therapeutic strategies to target tumors caused by the loss of these genes. In the present study, we report genome-scale CRISPR–Cas9 synthetic lethality screens in isogenic pairs of BRCA1- and BRCA2-deficient cells and identify CIP2A as an essential gene in BRCA1- and BRCA2-mutated cells. CIP2A is cytoplasmic in interphase but, in mitosis, accumulates at DNA lesions as part of a complex with TOPBP1, a multifunctional genome stability factor. Unlike PARP inhibition, CIP2A deficiency does not cause accumulation of replication-associated DNA lesions that require HR for their repair. In BRCA-deficient cells, the CIP2A–TOPBP1 complex prevents lethal mis-segregation of acentric chromosomes that arises from impaired DNA synthesis. Finally, physical disruption of the CIP2A–TOPBP1 complex is highly deleterious in BRCA-deficient tumors, indicating that CIP2A represents an attractive synthetic lethal therapeutic target for BRCA1- and BRCA2-mutated cancers. Durocher and colleagues identify CIP2A through synthetic lethal CRISPR screens as a key regulator of adaptive feedback mechanisms controlling chromosomal stability arising from accumulated DNA lesions in BRCA-mutated tumor cells.
- Published
- 2021
- Full Text
- View/download PDF